New hope for leukemia patients who run out of options
NCT ID NCT05657639
Summary
This study is testing whether a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) can help control acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. It will involve 68 patients aged 16-70 to see if this new combination is safe and more effective than current options. The goal is to find a better way to manage this aggressive form of blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.